Can Abilify and Eliquis Be Taken Together?
Yes, aripiprazole (Abilify) and apixaban (Eliquis) can be safely taken together without dose adjustment, as there is no clinically significant drug interaction between these medications.
Why This Combination is Safe
Aripiprazole and apixaban have different metabolic pathways that do not meaningfully interfere with each other:
- Aripiprazole is metabolized primarily by CYP3A4 and CYP2D6 enzymes 1
- Apixaban is metabolized by CYP3A4 and is also a substrate for P-glycoprotein (P-gp) transporter 2, 3
The key distinction is that aripiprazole is neither a strong CYP3A4 inhibitor/inducer nor a P-gp modulator. The FDA label for Abilify explicitly lists only strong CYP3A4 inhibitors (like itraconazole, clarithromycin) and strong CYP3A4 inducers (like carbamazepine, rifampin) as requiring dose adjustments 1. Aripiprazole does not fall into either category.
When Eliquis Dose Adjustment IS Required
For context, apixaban requires dose reduction only when combined with dual P-gp AND strong CYP3A4 inhibitors such as 3:
- Ketoconazole
- Itraconazole
- Ritonavir
Guidelines emphasize that apixaban interactions are most clinically significant when drugs affect both P-gp and CYP3A4 simultaneously 2. Single-pathway interactions (affecting only CYP3A4 or only P-gp) have less pronounced effects on apixaban levels 2.
Clinical Bottom Line
No dose adjustment is needed for either medication when used together. Continue both medications at their standard prescribed doses. The Abilify label confirms no dosage adjustment is necessary for CYP3A4 substrates when coadministered with aripiprazole 1, and aripiprazole lacks the dual inhibitory properties that would trigger apixaban dose reduction per the Eliquis label 3.
Important Monitoring Considerations
While the combination is safe from a drug interaction standpoint, monitor for:
- Bleeding risk from Eliquis (standard monitoring for any anticoagulant)
- Orthostatic hypotension from Abilify's alpha1-adrenergic antagonism 1
- These are independent medication effects, not interaction-related concerns